期刊文献+

塞来昔布联合三苯氧胺对甲基亚硝基脲诱导大鼠乳腺肿瘤的影响

Celecoxib combined with tamoxifen prevents methylnitrosourea-induced breast tumor in rats
下载PDF
导出
摘要 目的:塞来昔布联合三苯氧胺对甲基亚硝基脲(MNU)诱发大鼠乳腺肿瘤的影响。方法:雌性3周龄SPF级SpragueDawley(SD)大鼠140只随机分成对照组、塞来昔布组、三苯氧胺组及联合组,腹腔注射MNU后分别给予不同的方案进行干预,观察各组大鼠乳腺肿瘤的发生率、肿瘤的体积及COX-2和C-erbB-2的表达。结果:塞来昔布组、三苯氧胺组与对照组比较,肿瘤发生率低,肿瘤体积小;联合组肿瘤发生率最低,肿瘤体积最小。塞来昔布组、联合组大鼠乳腺肿瘤COX-2、C-erbB-2的阳性表达率低于对照组和三苯氧胺组(P<0.05)。结论:塞来昔布和三苯氧胺对MNU诱发大鼠乳腺肿瘤的发生均有预防抑制作用,两药联合效果更好。 Objective: The present study aims to evaluate the chemopreventive effect of celecoxib combined with tamoxifen on breast tumor induced by methylnitrosourea (MNU) in rats. Methods: A total of 140 SD female rats were injected with MNU to estab- lish breast tumor models. The rats were divided subsequently into control, celecoxib, tamoxifen, and combination groups. The occur- rence rates, volumes of breast tumor, and expression levels of cyclo0xygenase 2 (COX-2) and c-erbB-2 were observed. Results: The tu- mor occurrence rates were lower in the celecoxib and tamoxifen groups than in the control group. The combination group exhibited the lowest tumor-occurrence rate. The tumor volumes of the celecoxib and tamoxifen groups were lower than that of the control group. The combination group had the least tumor volume. The positive rates of COX-2 and c-erbB-2 in the celecoxib and combination groups were lower than those in the control and tamoxifen groups (P〈0.05). Conclusion: The combination of celecoxib and tamoxifen can sig- nificantly suppress MNU-induced breast tumor in female rats.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第14期824-827,共4页 Chinese Journal of Clinical Oncology
基金 广东省科技计划项目(编号:2009B060700075)资助~~
关键词 乳腺肿瘤 化学预防 环氧化酶-2 塞来昔布 三苯氧胺 breast tumor, chemoprevention, cyclooxygenase 2, celecoxib, tamoxifen
  • 相关文献

参考文献15

  • 1Nakatsugi S, Ohta T, Kawamori T, et al. Chemoprevenfion by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-ami- no-l-methyl-6-phenylimidazo[4,5-b] pyridine (PhlP) induced mammary gland carcinogenesis in rats[J]. Jpn J Cancer Res, 2000, 91 (9):886-892.
  • 2Ristimaki A, Sivula A, LundinJ, et al. Prognostic significance of ele- vated cyclooxygenase-2 expression in breast cancer[J]. Gancer Res, 2002, 62:632-635.
  • 3Wulfing P, Diallo R. Analysis of cyclooxygenase-2 expression in human breast cancer:high throughout tissue microarray analysis[J]. J Gancer Res Glin Oncol, 2003, 129(7):375.
  • 4Jana D, Sarkar DK, Maji A, et al. Can cyclo-oxygenase-2 be a use- ful prognostic and risk stratification marker in breast cancer?[J]. In- dian Med Assoc, 2012, 110(7) :429-433.
  • 5王西京,代志军,刘小旭,康华峰,赵世平,薛锋杰.乳腺癌中COX-2、HER-2的表达及其相关性[J].西安交通大学学报(医学版),2004,25(2):176-178. 被引量:6
  • 6Singh B, Cook KR, Vincent L, et al. Cyclooxygenase-2 induces ge- nomic instability, BCL-2 expression, doxorubicin resistance, and al- tered cancer-initiating cell phenotype in MCF7 breast cancer cells [J].J Surg Res, 2008, 147(2):240-246.
  • 7Oliveira VM, Piato S, Silva MA. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in sire, and adjacent normal epithelium [J]. Breast Cancer Res Treat, 2006, 95(3):235-241.
  • 8Salhab M, Singh-Ranger G, Mokelb R, et al. Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer[J].J Surg Oncol, 2007, 96(5):424-428.
  • 9周士珍,吴强,吴正升,凌晓光,杨枫.乳腺癌中环氧化酶-2的表达及其与VEGF、MVD、MMP-9、TIMP-1的关系[J].临床与实验病理学杂志,2005,21(4):442-445. 被引量:14
  • 10Timoshenko AV, Chakraborty C, Wagner GF, et al. COX-2-me- diated stimulation of the lymphangiogenic factor VEGF-C in hu- man breast cancer[J]. BrJ Cancer, 2006, 94(8):1154-1163.

二级参考文献37

  • 1[4]Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer [ J]. Oncol Rep, 1999, 6(1):71-73.
  • 2[5]Harris RE, Alshafie GA, Abou Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor [J].Cancer Res, 2000, 60(8) :2101-2103.
  • 3[6]Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer [J].Cancer Res, 2002, 62(3):632-635.
  • 4[7]DiGiovanna MP, Chu P, Davison TL, et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates [J].Cancer Res, 2002, 62(22) :6667-6673.
  • 5[8]Subbaramaiah K, Norton L, Gerald W, et al. Cyclooxygenase-2 is overexpressed in her-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3 [J]. J Biol Chem, 2002, 277(21): 18649- 18657.
  • 6[1]Parrett ML, Harris RE, Joarder FS, et al. Cyclooxygenase-2 expression in human breast cancer [J]. Int J Oncol, 1997,10(6):503-507.
  • 7[2]Eli Y, Przedecki F, Levin G, et al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo [J]. Biochem Pharmacol, 2001,61(5):565-571.
  • 8[3]Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors [J]. Cancer, 2000, 89(12):2637- 2645.
  • 9Tsujii M, Kawano S, DuBois RN. Cyclooxygenases-2 expression in human colon cancer cells increases metastatic potential[J]. Proc Natl Acad Sic USA, 1997, 94 (7):3336-40.
  • 10Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors[J]. Cancer, 2000, 89 (12) :2637-45.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部